Through the first rotavirus season after vaccination (n=5,673):

• Efficacy against mild, moderate, and severe rotavirus gastroenteritis caused by rotavirus serotypes G1, G2, G3, or G4 through the 2 rotavirus seasons after vaccination was 71%. The efficacy of RotaTeq beyond the second season postvaccination was not evaluated.
  
  
• Click here for more information on REST
• Click here for serotype-specific efficacy data
• RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks.
• The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

Select safety information

• RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.
• No safety or efficacy data are available for the administration of RotaTeq to infants who are potentially immunocompromised or to infants with a history of gastrointestinal disorders.
• Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.
• In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.
• In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.
• RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq, please read the Prescribing Information
and Patient Product Information.

RotaTeq is a registered trademark of Merck & Co., Inc.